miR-191在非小细胞肺癌中的表达及其临床意义

目的:探讨miR-191在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的表达及其临床意义。方法:采用实时荧光相对定量聚合酶链式反应(quantitative realtime polymerase chain reaction,qRT-PCR)技术检测非小细胞肺癌患者的癌组织及癌旁组织中miR-191的表达水平,并分析其与患者临床病理特征及生存期的相关性。结果:与癌旁组织比较,癌组织中miR-191的表达显著上调。组织分化程度低或有淋巴结转移的NSCLC患者癌组织中miR-191表达明显高于组织分化程度高或无淋巴结转移的NSCLC患者(P0.05),癌组织高表达miR-191的NSCLC患者生存期明显短于癌组织低表达miR-191的NSCLC患者(P0.05)。结论:miR-191在非小细胞肺癌中表达上调,与组织分化程度、淋巴结转移和患者生存期有关。     

共刺激因子B7-H1和B7-H3蛋白表达与胆囊癌病例特征相关

本研究选取2015年3月至2017年5月在我院保存的胆囊癌标本55例,同选取癌旁正常组织(距癌边缘>5 cm)作为对照,采用免疫组化染色检测B7-H1和B7-H3蛋白表达,分析B7-H1和B7-H3表达与胆囊癌临床病理特征和预后的关系,探讨共刺激因子B7-H1和B7-H3蛋白在胆囊癌中的表达及意义。研究结果表明:胆囊癌组织B7-H1和B7-H3蛋白阳性表达率分别为76.36%和63.63%,明显高于癌旁组织(p<0.05);B7-H1蛋白表达与胆囊癌TNM分期、淋巴结转移和侵袭深度有关(p<0.05);B7-H3蛋白表达与胆囊癌TNM分期、分化程度、淋巴结转移和侵袭深度有关(p<0.05);胆囊癌组织中B7-H1与B7-H3蛋白表达呈正相关(rs=0.516, p<0.05);B7-H1和B7-H3表达双阳性者和B7-H1或B7-H3单一表达阳性者中位总生存时间分别为20个月和21个月,明显低于B7-H1和B7-H3表达双阴性者组,差异比较有统计学意义(p<0.05)。本研究结论认为:B7-H1和B7-H3蛋白表达与胆囊癌病理特征有关系,两者间有一定相关性,且与患者预后有关。     

B7-H4和FOXP3在乳腺癌中的表达及临床意义

目的:研究B7-H4和FOXP3在乳腺癌中的表达及其相互关系和临床意义.方法:应用S-P免疫组化法检测B7-H4蛋白和FOXP3蛋白在11例正常乳腺、25例乳腺良性病变、272例乳腺癌组织中的表达情况;运用原位杂交检查B7-H4 mRNA在10例正常乳腺、10例良性病变、20例乳腺癌组织中的表达情况.结果:B7-H4蛋白在乳腺癌中的阳性表达率(83.39%)高于乳腺良性病变组(64.00%)和乳腺正常组(54.55%),差异有统计学意义(p＜0.05);FOXP3在乳腺癌中的阳性表达率(82.67%)高于乳腺良性病变组(60.00%)和乳腺正常组(54.55%),差异有统计学意义(p＜0.05);B7-H4和FOXP3在乳腺癌中的阳性表达率与患者年龄、肿块大小和组织学分型无关(p＞0.05),而与组织学分级和淋巴结转移相关(p＜0.05);B7-H4和FOXP3在乳腺癌组织中的表达呈正相关(r=0.306,p＜0.001);B7-H4 mRNA在正常乳腺组、乳腺良性病变组、乳腺癌组中的阳性表达率差异没有统计学意义(p＞0.05);B7-H4 mRNA在乳腺癌中的阳性表达率与年龄、肿块大小、组织学分级、淋巴结转移无关(p＞0.05).结论:B7-H4和FOXP3在乳腺癌中表达上调,可能与乳腺癌的转移和预后相关.     

波形蛋白在非小细胞肺癌组织中的表达及其临床意义

目的:探究波形蛋白在非小细胞肺癌(NSCLC)组织中的表达及其与肺癌浸润转移的相关性。方法:收集2012年6月-2014年6月我院手术切除的NSCLC癌组织标本150例及癌旁正常组织(距肿瘤5 cm)79例,提取两组的RNA,采用实时荧光定量聚合酶链反应(RT-PCR)检测波形蛋白m RNA表达水平,免疫组化法检测波形蛋白的蛋白表达,分析波形蛋白表达水平与淋巴结转移、TNM分期的相关性。结果:波形蛋白m RNA在NSCLC癌组织中的表达明显高于癌旁正常组织(P0.05)。NSCLC癌组织中波形蛋白m RNA表达水平的上调与淋巴结转移及TNM分期(P0.05)相关。结论:波形蛋白在NSCLC患者中表达异常升高,与NSCLC的发生和浸润转移密切相关。     

B7-H1和B7-H4在口腔鳞状细胞癌组织中的表达及临床意义

目的:探讨口腔鳞状细胞癌(Oral Squamous Cell Carcinoma,OSCC)中B7-H1和B7-H4的表达及其临床意义,并为OSCC的临床诊断、治疗、判断预后及预防等提供依据。方法:采用免疫组织化学S-P法检测B7-H1及B7-H4在60例OSCC及20例非肿瘤患者正常口腔黏膜组织(NOM)中的表达情况,分析两者与OSCC临床病理特征的相关性。结果:B7-H1在OSCC组织中表达显著高于在NOM组织中表达(29例,48.3%v4例,20%,x~2=4.969,P0.05);B7-H4在OSCC组织中表达亦显著高于在NOM组织中表达(31例,51.7%v5例,25%,x~2=4.310,P0.05)。B7-H1与B7-H4在OSCC组织的表达都与TNM分期、淋巴结转移和肿瘤分化程度显著相关(P0.05),而与年龄、性别及肿瘤直径大小等无关。OSCC组织中B7-H1和B7-H4的高表达呈显著性正相关性(x~2=5.613 P0.05),60例组织中B7-H1和B7-H4共表达现象有11例(18.3%),NOM中未发现两者共表达现象。结论:B7-H1和B7-H4过表达与OSCC发生、发展及预后有关,可以作为预后指标。     

NF-κB与Slug在非小细胞肺癌及其上皮间质转化中的作用

目的:研究核因子NF-κB与slug在非小细胞肺癌(NSCLC)中的表达情况、及二者与非小细胞肺癌上皮间质转化(EMT)的关系,为非小细胞肺癌的诊断治疗提供理论依据.方法:(1)采用免疫组化PV9000二步法测定50例NSCLC组织及20例相应正常肺组织中NF-κBP65、slug、E-cadherin及Vimentin蛋白表达情况.(2)采用RT-PCR测定其中25例NSCLC组织及10例相应正常肺组织中NF-κBP65、slug的mRNA表达情况.结果:NSCLC中NF-κBP65蛋白表达量高于癌旁正常肺组织(Z=-2.370,P＜0.05),NF-κBP65mRNA表达量明显高于癌旁正常肺组织(t=4.967,P＜0.01);Slug蛋白表达量明显高于癌旁正常肺组织(Z=-4.443,P＜0.01),SlugmRNA表达量明显高于癌旁正常肺组织(t=6.483,P＜0.01).在NF-kBP65阳性癌组织中,E-cadherin蛋白表达下降(x2=5.024,P＜0.05),Vimentin蛋白表达上升(x2=4.723,P＜0.05);Slug阳性癌组织中,E-cadherin蛋白表达下调(x2=5.984,P＜0.05),Vimentin表达上调(x2=5.028,P＜0.05).另外,NF-kBP65与Slug在蛋白水平呈极显著正相关(r=0.443,P＜0.01),在mRNA水平呈显著正相关(r=0.439,P＜0.05).NF-κB与分化程度(x2=5.024,P＜0.05)、有无淋巴结转移(x2=7.933,P＜0.01)及肿瘤的分期(x2=5.614,P＜0.05)有关,与性别、年龄、组织类型无明显相关性(P＞0.05);Slug与淋巴结转移(x2=6.174,P＜0.05)及肿瘤的分期(x2=7.317,P＜0.01)有关,与性别、年龄、组织类型、分化程度无明显相关性(P＞0.05).结论:NF-κB、slug在NSCLC中表达增强,可能与NSCLC的发生、发展、转移有关;并且NF-κB与Slug可能协同抑制E-cadherin表达,促进Vimentin表达,诱使NSCLC的EMT发生,从而为进一步研究NSCLC的EMT提供理论依据.     

Egfl7 与非小细胞肺癌上皮间质转化关系的研究

目的:研究Egfl7与非小细胞肺癌(NSCLC)上皮间质转化标志物E-cadherin,Vimentin的相关性,探讨Egfl7是否参与NSCLC的上皮间质转化(EMT)。方法:分别采用免疫组化法和RT-PCR法检测40例NSCLC组织和20例肺癌旁正常肺组织中Egfl7,E-cadherin和Vimentin蛋白和mRNA的表达情况。结果:1).NSCLC组织中的Egfl7蛋白和mRNA的表达水平明显高于癌旁正常肺组织;其差异有统计学意义(P<0.05)。Egfl7的表达水平与肺癌的临床分期、及淋巴结转移密切相关(p0.05)。结论:NSCLC组织中Egfl7高表达,Egfl7可能与NSCLC的侵袭性相关;Egfl7与E-cadherin呈负相关,与Vimentin表达成正相关,Egfl7可能参与了NSCLC患者的上皮间质转化(EMT)过程,阻断Egfl7信号可能会抑制NSCLC患者的ENT。     

PTTG和VEGF在NSCLC中的表达及相关性研究

目的:探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)中PTTG和VEGF蛋白的表达相关性及其与肺癌发展之间的关系。方法:应用免疫组织化学SP法检测57例NSCLC组织及6例良性病变肺组织中PTTG和VEGF蛋白的表达。结果: NSCLC组织PTTG和VEGF蛋白的阳性表达率分别为82．5%和77．2%,在良性病变肺组织中均未检测到两者的表达。上述两种组织之间的PTTG和VEGF蛋白表达均有显著性差异(P＜0．05)。PTTG和VEGF蛋白表达与TNM分期和淋巴结转移密切相关(P＜0．05),与患者的性别、年龄、肿瘤大小、病灶部位、组织学类型及分化程度无关(P＞0．05)。癌组织中PTTG和VEGF蛋白的表达呈显著正相关(r=0．385,P=0．003)。结论:PTTG和VEGF在非小细胞肺癌中高表达,两基因表达成显著正相关,与非小细胞肺癌的发展及转移关系密切。     

标准型CD44基因蛋白在78例非小细胞肺癌中表达的定量研究

目的　探讨标准型CD44 (CD44s)基因表达与非小细胞肺癌 (NSCLC)的组织学类型、分化程度以及转移等之间的关系。方法　应用微波 -LSAB免疫组化染色及图像分析 ,测定了 78例NSCLC中CD44s阳性产物的光密度值(IOD)与组织学类型、分化程度和淋巴结转移间的关系。结果　 78例NSCLC的CD44s阳性细胞IOD值 (12 9.8± 12 .2 )与 10例癌旁组织IOD值 (91.3± 11.5 )之间差异非常显著 (P <0 .0 1) ;有淋巴结转移组 (10 9.8± 13.2 )与无淋巴结转移组 (136 .5± 14.8)间差异非常显著 (p <0 .0 1)。组织学类型、不同分化程度之间差异无显著性 (P >0 .0 5 )。结论　CD44s强阳性的病人转移率低、预后良好 ,CD44s可作为预测NSCLC病人预后的指标。     

Fibulin3基因在非小细胞肺癌中的蛋白表达及甲基化检测

目的:检测Fibulin3基因在非小细胞肺癌患者(non-small cell hung cancer,NSCLC)组织中的表达和甲基化状态,并分析其临床病理意义.方法:收集59例NSCLC患者术后病理蜡块,进行免疫组化染色;提取癌组织及相应癌旁组织DNA,甲基化特异性聚合酶链反应(MSP)检测Fibulin3基因启动子区甲基化情况.结果:59例NSCLC标本中,25例(42.4%)Fibulin3表达水平比相应癌旁组织下调(P＜0.05);癌组织和相应癌旁组织甲基化22例和5例检出Fibulin3基因启动子区高甲基化,其阳性率分别为37.3%和8.5%,差异具有统计学意义(P＜0.001);Fibulin3启动子甲基化导致蛋白表达下调或缺失(P＜0.001),并与临床分期(P=0.035)及淋巴结转移(P=0.011)相关.结论:启动子甲基化引起的Fibulin3基因失活在NSCLC发生发展中起重要作用,Fibulin3启动子甲基化可能成为NSCLC早期诊断和预后评估的潜在标记物.     

B7-H4 expression associates with cancer progression and predicts patient’s survival in human esophageal squamous cell carcinoma

A retrospective cohort study including 112 patients suffering from esophageal squamous cell carcinoma (ESCC) was performed to investigate the expression of B7-H4 in ESCC and determine its association with patient’s clinicopathological parameters and survival. Expression levels of B7-H4 on tumor cells and densities of tumor infiltrating lymphocytes (TILs) in the surgical specimens of ESCC tissues were characterized using immunohistochemical assays. Uni- and multivariate analyses were performed to evaluate the prognostic value of B7-H4 expression levels and densities of TILs in tumor sections. Positive B7-H4 immunostaining was observed in 107 of 112 (95.5%) of ESCC tissue sections. We further divided all patients into two major subgroups, a lower B7-H4 expression group with 46 patients and a higher B7-H4 expression group with 66 patients. We found that expression levels of B7-H4 on tumor cells were significantly correlated with patient’s gender (P = 0.0288), distant metastasis (P = 0.0500), and TNM stage (P = 0.0258). Moreover, tumor cell B7-H4 expression was inversely correlated with densities of CD3⁺ T cells in tumor nest (P = 0.0424) and CD8⁺ T cells in tumor stroma (P = 0.0229). The overall survival rate of the patients with higher B7-H4 expression was significantly worse than that of the patients with lower B7-H4 expression (P = 0.0105, Hazard Ratio: 1.854, 95%CI:1.152–2.902). Markers of cell-mediated immune responses such as CD3, CD8, and T-bet were associated with better patient survival. The present study demonstrated that B7-H4 expression in human ESCC is associated with cancer progression, reduced tumor immunosurveillance and worse patient outcomes. B7-H4 can serve as a novel prognostic predictor for human ESCC and a potential target for the immune therapy against this malignancy.     

非小细胞肺癌组织KIF2A、KIF2C、KIF20A mRNA表达与临床病理特征和预后的关系

摘要 目的：探讨非小细胞肺癌（NSCLC）组织驱动蛋白超家族成员2A（KIF2A）、驱动蛋白超家族成员2C（KIF2C）、驱动蛋白超家族成员20A（KIF20A）信使核糖核酸（mRNA）表达与临床病理特征和预后的关系。方法：选择2016年9月至2019年9月天津医科大学总医院手术切除的NSCLC患者106例,取其癌组织及其对应的癌旁组织,应用荧光定量聚合酶链式反应（RT-qPCR）检测组织中KIF2A、KIF2C、KIF20A mRNA表达,分析其与临床病理特征的关系。应用 Pearson相关性分析NSCLC组织中KIF2A、KIF2C、KIF20A mRNA表达间的关系。随访3年,应用Kaplan-Meier生存曲线分析KIF2A、KIF2C、KIF20A mRNA表达与患者预后关系。结果：NSCLC癌组织中KIF2A、KIF2C、KIF20A mRNA表达水平显著高于癌旁组织（P<0.05）。低分化、淋巴结转移、临床分期Ⅲ A 期NSCLC癌组织中KIF2A、KIF2C、KIF20A mRNA表达水平显著高于中高分化、无淋巴结转移及临床分期I、II期NSCLC癌组织（P<0.05）。Pearson相关分析显示,NSCLC癌组织中KIF2A mRNA表达与KIF2CmRNA、KIF20A mRNA表达呈正相关,KIF2C mRNA表达与KIF20A mRNA表达呈正相关（P<0.05）。Kaplan-Meier法分析显示KIF2A mRNA低表达组、KIF2C mRNA低表达组、KIF20A mRNA低表达组3年生存率分别为（84.78%,86.27%,81.48%）显著高于KIF2A mRNA高表达组、KIF2C mRNA高表达组、KIF20A mRNA高表达组（59.62%,55.32%,59.09%）（P<0.05）。结论：KIF2A、KIF2C、KIF20A mRNA在NSCLC组织中存在高表达,且与低分化、淋巴结转移、临床分期及预后有关。     

Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma

B7-H3, a member of the B7-family molecules, plays an important role in adaptive immune responses, and was shown to either promote or inhibit T-cell responses in various experimental systems. B7-H3 was expressed in some human cancers and correlated with poor outcome of cancer patients. However, its exact role in cancer is not known. In the present study, we studied the expression of B7-H3 in the pathologic specimens of 102 patients treated for colorectal carcinoma (CRC) by immunohistochemistry. Strong B7-H3 expression was found in cancer tissues from 54.3% CRC patients, while minimal expression was found in adjacent normal colorectal tissues. Higher B7-H3 expression in tumor positively correlated with a more advanced tumor grade. In addition, consistent with a role of B7-H3 in suppressing tumor immune surveillance, the expression of B7-H3 in cancer cells negatively correlated with the intensity of tumor infiltrating T lymphocytes in both tumor nest and tumor stroma. Furthermore, we found that the level of soluble B7-H3 in sera from CRC patients was higher than healthy donors. TNF-α, an important cancer-promoting inflammatory molecule, was subsequently found to significantly increase the release of soluble B7-H3 in colon cancer cell lines. Therefore, our data suggest that both soluble and membranous B7-H3 proteins are involved in colon cancer progression and evasion of cancer immune surveillance.     

B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence

B7-H3, a novel B7 family member, positively or negatively regulates T-cell responses. We investigated the clinical relevance and prognostic significance of B7-H3 in hepatocellular carcinoma (HCC). Western blotting showed B7-H3 upregulation in 17 of 24 (70.8 %) HCC tissues compared with nontumor liver tissues (p = 0.028). B7-H3 immunostaining on tissue microarrays containing 240 HCC patient samples indicated that 225 (93.8 %) tumors had aberrant B7-H3 expression, with strong intensity in 79 (32.9 %) cases, whereas B7-H3 expression in peritumor liver cells was weak in most cases (226; 94.2 %). Notably, patients with high/moderate tumor cell B7-H3 expression showed significantly poorer survival (p = 0.009) and increased recurrence (p = 0.002). After multivariable adjustment, high/moderate B7-H3 expression remained significant for an increased risk of recurrence (hazard ratio = 1.79; 95 % confidence interval = 1.19–2.70; p = 0.005). B7-H3 expression correlated with invasive phenotypes like vascular invasion and advanced tumor stage, and the metastatic potential of HCC cell lines. Flow cytometry showed that B7-H3 expression is inversely correlated with proliferation and interferon-γ production by infiltrating T cells. Interferon-γ stimulation significantly upregulated B7-H3 expression in HCC cells in vitro, implicating B7-H3 expression as a feedback mechanism to evade anti-tumor immunity. Importantly, the prognostic value of B7-H3 expression was validated in an independent cohort of 206 HCC patients. Collectively, our data suggest that B7-H3 was abundantly expressed in HCC and was associated with adverse clinicopathologic features and poor outcome. Thus, B7-H3 represents an attractive target for diagnostic and therapeutic manipulation in human HCC.     

B7-H3 is Overexpressed in Patients Suffering Osteosarcoma and Associated with Tumor Aggressiveness and Metastasis

B7-H3 is a member of the B7-family of co-stimulatory molecules, which has been shown to be broadly expressed in various tumor tissues, and which plays an important role in adaptive immune responses. The role of B7-H3 in osteosarcoma, however, remains unknown. In this study we used immunohistochemistry to analyze B7-H3 expression in 61 primary osteosarcoma tissues with case-matched adjacent normal tissues, and 37 osteochondroma and 20 bone fibrous dysplasia tissues. B7-H3 expression was expressed in 91.8% (56/61) of the osteosarcoma lesions, and the intensity of B7-H3 expression in osteosarcoma was significantly increased compared with adjacent normal tissues, osteochondroma and bone fibrous dysplasia tissues (p<0.001). Patients with high tumor B7-H3 levels had a significantly shorter survival time and recurrence time than patients with low tumor B7-H3 levels (p<0.001). Moreover, tumor B7-H3 expression inversely correlated with the number of tumor-infiltrating CD8⁺ T cells (p<0.05). In vitro, increasing expression of B7-H3 promotes osteosarcoma cell invasion, at least in part by upregulating matrix metalloproteinase-2 (MMP-2). In conclusion, our study provides the first evidence of B7-H3 expression in osteosarcoma cells as a potential mechanism controlling tumor immunity and invasive malignancy, and which is correlated with patients’ survival and metastasis.     

Cyclin B1、P34cdc2在非小细胞肺癌中的表达及意义

目的为了研究非小细胞肺癌组织中Cyclin B1及P34cdc2的表达,探讨Cyclin B1及P34cdc2的表达与非小细胞肺癌临床病理特征的关系.方法随机收集非小细胞肺癌(含癌旁细支气管和/或小支气管增生组织和正常肺组织)标本100例.采用免疫组织化学SP法.结果显示在癌组织与癌旁细支气管和/或小支气管上皮增生组织及正常肺组织中Cyclin B1及P34cdc2表达差异有显著性(P＜0.01).在癌组织中有过表达;在癌旁细支气管和/或小支气管上皮增生组织中的表达较正常肺组织中的表达增强.100例非小细胞肺癌组织中Cyclin B1及P34cdc2表达呈正相关(P＜0.01),相关系数为0.966.癌旁细支气管和/或小支气管上皮增生组织中,Cyclin B1及P34cdc2的表达也呈正相关(P＜0.01),相关系数为0.638.组织类型、分化程度和淋巴结转移与Cyclin B1及P34cdc2的表达均无统计学意义(P＞0.05).不同临床分期的非小细胞肺癌,其Cyclin B1及P34 cdc2的表达差异有显著性(P＜0.05).结论 Cyclin B1及P34cdc2在非小细胞肺癌中有过表达现象,二者在M期前形成过多的促成熟因子(maturation promoting factor, MPF)从而加速非小细胞肺癌细胞跨越G2/M期关卡进入分裂期.过表达的Cyclin B1及P34cdc2可作为反映非小细胞肺癌细胞分裂增殖能力和临床分期的指标之一.     

CiRS‐7 targeting miR‐7 modulates the progression of non‐small cell lung cancer in a manner dependent on NF‐κB signalling

The purpose of this study was to figure out the effect of ciRS‐7/miR‐7/NF‐κB axis on the development of non‐small cell lung cancer (NSCLC). In response, the expressions of ciRS‐7, miR‐7 and NF‐κB subunit (ie RELA) within NSCLC tissues and cell lines were determined with real‐time polymerase chain reaction (RT‐PCR) and Western blot. Moreover, the NSCLC cells were transfected with pcDNA3‐ciRS‐7‐ir, pcDNA3‐ciRS‐7, miR‐NC and miR‐7 mimic. Furthermore, the targeted relationships between ciRS‐7 and miR‐7, as well as between miR‐7 and RELA, were confirmed by luciferase reporter assay. The proliferation, migration and apoptosis of NSCLC cells were, successively, measured using CCK‐8 assay, wound‐healing assay and flow cytometry test. Consequently, ciRS‐7, miR‐7, histopathological grade, lymph node metastasis and histopathological stage could independently predict the prognosis of patients with NSCLC (all P < .05). Moreover, remarkably up‐regulated ciRS‐7 and RELA expressions, as along with down‐regulated miR‐7 expressions, were found within NSCLC tissues and cells in comparison with normal ones (P < .05). Besides, overexpressed ciRS‐7 and underexpressed miR‐7 were correlated with increased proliferation, migration and invasion, yet reduced apoptosis rate of NSCLC cells (P < .05). More than that, ciRS‐7 specifically targeted miR‐7 to reduce its expressions (P < .05). Ultimately, the NSCLC cells within miR‐7 + RELA group were observed with superior proliferative, migratory and invasive capabilities than those within miR‐7 group (P < .05), and RELA expression was also significantly modified by both ciRS‐7 and miR‐7 (P < .05). In conclusion, the ciRS‐7/miR‐7/NF‐kB axis could exert pronounced impacts on the proliferation, migration, invasion and apoptosis of NSCLC cells.